Marker Therapeutics, Inc. (MRKR)
0.9466
-0.06
(-6.28%)
USD |
NASDAQ |
Oct 13, 16:00
0.9466
0.00 (0.00%)
After-Hours: 17:05
Marker Therapeutics Net Income (Quarterly) : -1.826M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.826M |
| March 31, 2026 | -3.179M |
| December 31, 2025 | -1.703M |
| September 30, 2025 | -1.999M |
| June 30, 2025 | -4.016M |
| March 31, 2025 | -4.446M |
| December 31, 2024 | -3.838M |
| September 30, 2024 | -2.308M |
| June 30, 2024 | -2.193M |
| March 31, 2024 | -2.393M |
| December 31, 2023 | -2.740M |
| September 30, 2023 | -2.982M |
| June 30, 2023 | -4.099M |
| March 31, 2023 | -4.225M |
| December 31, 2022 | -3.043M |
| September 30, 2022 | -5.727M |
| June 30, 2022 | -9.244M |
| March 31, 2022 | -9.910M |
| December 31, 2021 | -9.763M |
| September 30, 2021 | -12.43M |
| June 30, 2021 | -10.91M |
| March 31, 2021 | -8.779M |
| December 31, 2020 | -8.507M |
| September 30, 2020 | -7.372M |
| June 30, 2020 | -6.342M |
| Date | Value |
|---|---|
| March 31, 2020 | -6.486M |
| December 31, 2019 | -5.079M |
| September 30, 2019 | -5.460M |
| June 30, 2019 | -5.570M |
| March 31, 2019 | -5.319M |
| December 31, 2018 | -135.56M |
| September 30, 2018 | -4.388M |
| June 30, 2018 | -4.813M |
| March 31, 2018 | -3.196M |
| December 31, 2017 | -2.683M |
| September 30, 2017 | -3.986M |
| June 30, 2017 | -1.893M |
| March 31, 2017 | -2.420M |
| December 31, 2016 | -1.577M |
| September 30, 2016 | -2.103M |
| June 30, 2016 | 5.974M |
| March 31, 2016 | -4.750M |
| December 31, 2015 | -17.12M |
| September 30, 2015 | 2.484M |
| June 30, 2015 | -18.45M |
| March 31, 2015 | -0.9817M |
| December 31, 2014 | -0.7365M |
| September 30, 2014 | -1.568M |
| June 30, 2014 | 0.7535M |
| March 31, 2014 | -29.71M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.826M |
| EPS Diluted (Quarterly) | -0.0946 |
| Enterprise Value | 4.918M |
| Earnings Yield | -50.78% |
| Normalized Earnings Yield | -50.77 |